Maxim Group Initiates Coverage On NeuroBo Pharmaceuticals With Buy Rating, Announces Price Target of $10
Maxim Group Initiates Coverage On NeuroBo Pharmaceuticals With Buy Rating, Announces Price Target of $10
Maxim集團以買入評級啓動對NeuroBO製藥的報道，宣佈目標股價爲10美元
Maxim Group analyst Jason McCarthy initiates coverage on NeuroBo Pharmaceuticals (NASDAQ:NRBO) with a Buy rating and announces Price Target of $10.
Maxim Group分析師Jason McCarthy開始對神經保健製藥（納斯達克：NRBO）進行覆蓋，給予買入評級，並公佈目標價爲10美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。